To examine changes in the folate concentrations in red cell during relatively long-term total parenteral nutrition (TPN), 10 Japanese patients with Crohn's disease (7 males), the mean Crohn's disease activity index on admission being 211, were given folic acid in a dose of 400 1tg/day (AMA-FDA formulation) or 800 big/day for 6-16 weeks (mean 10.5). The red cell folate concentrations were determined before TPN and once every week or 2-4 weeks thereafter. The folate concentrations were very low even after TPN with folic acid of 400 tcg/day. In those given 800 ltg of daily folic acid, the folate levels tended to increase, but did not reach the normal range. We propose that folic acid over 800 pg/day or a double dose of AMA-FDA formulation should be prescribed for Crohn's disease treated with long-term TPN.
Introduction
There has been no established drug therapy for Crohn's disease. Total parenteral nutrition (TPN) or elemental diet is a common and primary therapy for this disease, aimed at bowel rest.'-5 Most patients, however, are in a state of latent hypoalimentation before the therapy, because of extensive intestinal lesions or due to the lack of ingestion of nutrients. Therefore, various vitamin deficiencies, such as folic acid and vitamin D, can frequently occur in such 2 patients.
To establish the dose of vitamins required for TPN 
Results
The folate concentration in red cell prior to the therapy was 66 ± 38 ng/ml, being extremely low compared with a normal value (Figure 1 ). In group A (Cases 1-7) (400 fig/day of intravenous folic acid), red cell folate levels averaged 76 ng/ml at 8 weeks from the initiation of therapy (n = 7) and 1 3 ng/ml at 16 weeks (n = 3). In group B (Cases 8-10; 800 gig/day), folate levels increased with time and averaged 138 ng/ml at 6 weeks of the therapy. In a particular case (case 8) it continuously and progressively rose to a maximum of 249 ng/ml at 10 weeks. In 9 cases, TPN led to clinical remission at 8-16 weeks of the therapy; CDAI improved from 209 to 74 on average, and radiography or endoscopy also revealed a remarkable improvement. The remaining one case (case 10) showed a poor clinical response with TPN, and underwent an operation for stricture of the ileum after 6 weeks of therapy.
In 5 cases, mild anaemia (haemoglobin concentration: 9.5-10.3 g/lOOml) was evident prior to TPN therapy, but improved gradually and disappeared at 8-16 weeks of the therapy. In the remaining 5, however, haemoglobin concentration was within normal limits prior to and during TPN therapy. Megaloblastic anaemia due to folic acid deficiency was evident in none of the cases during this study period. Discussion TPN has been prescribed for patients with Crohn's disease, the objective being to improve the nutritional state and/or to induce remission ofthis disease in those who fail to respond to drugs. In recent years, TPN has been used as a primary therapy for Crohn's disease,3'5,9 and sustained remission has also been reported in those given long-term therapy. Folic acid deficiency can occur in patients with Crohn's disease. Hoffbrand et al." examined 64 patients and found very low serum levels offolate in 22 patients who required hospitalization. In 5 of 7 patients for whom assay was feasible, they also found a decrease in the red cell folate concentration. Elsborg and Larsen'2 also observed decreased serum folate levels in 35 patients with Crohn's disease and attributed this to dietary insufficiency, malabsorption, and increased cell turnover.
Although the serum folate level is commonly used as a sensitive indicator for folic acid deficiency, serum folate varies with temporary changes in the intrahepatic storage or oral intake offolic acid and is also susceptible to haemolysis at the time of blood sampling. In contrast, folate concentration in red cell is relatively independent of circumstantial factors and more accurately reflects the amount of folic acid retained in the body, thus serving as a more useful index. '3 In the present study, serial changes in the red cell folate were determined in patients with Crohn's disease who received folic acid of400 1tg/day (a dose of AMA-FDA formulation) or of 800 jig/day during a relatively long-term TPN. The levels of folate were far below the normal range before TPN and remained very low during an average of 10.5 weeks ofTPN with daily folic acid of 400 ytg. In contrast, the levels in those who received a double dose of folic acid tended to increase but never reached the normal value.
The occurrence of hypervitaminosis due to an excessive administration of folic acid is rare. Hunter et al. ' 4 have reported that healthy subjects given intramuscular folic acid of 15,000pg/day developed mental changes, sleep disturbance, and gastrointestinal symptoms. Such symptoms, however, were not documented in our cases treated with folic acid. From these findings, folic acid of more than double the dose of the AMA-FDA formulation is considered to be necessary in patients with Crohn's disease with or without long-term TPN therapy.
